Evidence map›Paper›PMID 33704817›Full record

ArticleClinical cardiology2021

Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans.

Carolyn S P Lam, Robert Wood, Muthiah Vaduganathan, Hector Bueno, Alex Chin, Gabriela Luporini Saraiva, Elisabeth Sörstadius, Theo Tritton, Joseph Thomas, Lei Qin

Abstract read
In one paragraph

Article in Clinical cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carolyn S P LamNational Heart Centre Singapore & Duke-National University of Singapore Medical School, Singapore.ORCID https://orcid.org/0000-0003-1903-0018
Robert WoodAdelphi Real World, Bollington, UK.ORCID https://orcid.org/0000-0002-6977-435X
Muthiah VaduganathanAstraZeneca, Gaithersburg (Consultant), Maryland, USA.
Hector BuenoCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Alex ChinAstraZeneca, Gaithersburg (Consultant), Maryland, USA.
Gabriela Luporini SaraivaAstraZeneca, Gaithersburg (Consultant), Maryland, USA.
Elisabeth SörstadiusAstraZeneca, Gothenburg, Sweden.
Theo TrittonAdelphi Real World, Bollington, UK.
Joseph ThomasAdelphi Real World, Bollington, UK.
Lei QinAstraZeneca, Gaithersburg (Consultant), Maryland, USA.

Funding

AstraZeneca
6 · The paper itself

Abstract

backgroundLimited real-world data exist on healthcare resource utilization (HCRU) and associated costs of patients with heart failure (HF) with reduced ejection fraction (HFrEF) and preserved EF (HFpEF), including urgent HF visits, which are assumed to be less burdensome than HF hospitalizations (hHFs) HYPOTHESIS: This study aimed to quantify the economic burden of HFrEF and HFpEF, via a retrospective, longitudinal cohort study, using IBM® linked claims/electronic health records (Commercial and Medicare Supplemental data only).

methodsAdult patients, indexed on HF diagnosis (ICD-10-CM: I50.x) from July 2012 through June 2018, with 6-month minimum baseline period and varying follow-up, were classified as HFrEF (I50.2x) or HFpEF (I50.3x) according to last-observed EF-specific diagnosis. HCRU/costs were assessed during follow-up.

resultsAbout 109 721 HF patients (22% HFrEF, 31% HFpEF, 47% unclassified EF; median 18 months' follow-up) were identified. There were 3.2 all-cause outpatient visits per patient-month (HFrEF, 3.3; HFpEF, 3.6); 69% of patients required inpatient stays (HFrEF, 80%; HFpEF, 78%). Overall, 11% of patients experienced hHFs (HFrEF, 23%; HFpEF, 16%), 9% experienced urgent HF visits (HFrEF, 15%; HFpEF, 12%); 26% were hospitalized less than 30 days after first urgent HF visit versus 11% after first hHF. Mean monthly total direct healthcare cost per patient was $9290 (HFrEF, $11 053; HFpEF, $7482).

conclusionsHF-related HCRU is substantial among contemporary real-world HF patients in US Commercial or Medicare supplemental health plans. Patients managed in urgent HF settings were over twice as likely to be hospitalized within 30 days versus those initially hospitalized, suggesting urgent HF visits are important clinical events and quality improvement targets.

Indexed as

Diabetes Mellitus, Type 2Heart FailureAdultAgedCost of IllnessFemaleHealth Care CoalitionsHumansLongitudinal StudiesMaleMedicarePrognosisRetrospective StudiesStroke VolumeUnited StatesVentricular Function, Leftcostejection fractionhealthcare resource utilizationheart failurereal world

Identifiers

PMID33704817
PMCPMC8119853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.